Oral small molecule GLP-1 receptor agonist
Orforglipron 45 mg oral once daily
ORFO_PO_45MG_QD
Related
- All doses pooled: Orforglipron tablet
- Orforglipron 12 mg oral once daily
- Orforglipron 36 mg oral once daily
- Orforglipron 6 mg oral once daily
- Orforglipron 3 mg oral once daily
- Orforglipron maximum tolerated dose tablet once daily
- Orforglipron 1 mg tablet once daily
- Orforglipron 14.5 mg tablet once daily
- Orforglipron 17.2 mg tablet once daily
- Orforglipron 0.8 mg tablet once daily
- Orforglipron 2.5 mg tablet once daily
- Orforglipron 5.5 mg tablet once daily
- Orforglipron 9 mg tablet once daily
- Orforglipron 24 mg oral once daily
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.40 (0.01 to 17.61) | 0.70 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 20 to 36 (target week 26) | Placebo | MD -3.39 (-8.03 to 1.24) | 0.56 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.42 (0.04 to 2.11) | 0.73 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 3.49 (1.90 to 6.30) | 0.39 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 7.28 (3.59 to 14.29) | 0.20 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 3.28 (1.72 to 5.98) | 0.20 |
| Type 2 diabetes (adults) | Constipation | longest follow-up | Placebo | HR 3.24 (1.38 to 7.23) | 0.24 |
| Type 2 diabetes (adults) | Gallbladder and biliary disease | longest follow-up | Placebo | HR 0.66 (0.01 to 51.93) | 0.56 |
| Type 2 diabetes (adults) | Acute pancreatitis | longest follow-up | Placebo | HR 0.85 (0.05 to 14.05) | 0.47 |
| Overweight or obesity without diabetes (adults) | Systolic blood pressure change | weeks 20 to 40 (target week 26) | Placebo | MD -8.38 (-18.54 to 3.47) | 0.78 |
| Overweight or obesity without diabetes (adults) | Percent body weight change | weeks 20 to 40 (target week 26) | Placebo | MD -9.69 (-16.67 to -1.16) | 0.62 |
| Overweight or obesity without diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 1.44 (0.20 to 8.79) | 0.44 |
| Overweight or obesity without diabetes (adults) | Nausea | longest follow-up | Placebo | HR 3.21 (1.75 to 5.72) | 0.56 |
| Overweight or obesity without diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 7.04 (3.16 to 15.51) | 0.31 |
| Overweight or obesity without diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 3.43 (1.44 to 7.77) | 0.26 |
| Overweight or obesity without diabetes (adults) | Constipation | longest follow-up | Placebo | HR 2.08 (0.78 to 5.36) | 0.50 |
Trials
- NCT05086445A Single- and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3502970 in Japanese Participants With Type 2 Diabetes Mellitus2021 · 62 randomized · 12 weeks
- NCT05048719A Phase 2 Study of Once-Daily LY3502970 Compared With Placebo and Once-Weekly Dulaglutide in Participants With Type 2 Diabetes Mellitus2021 · 383 randomized · 26 weeks
- NCT05051579A Phase 2 Study of Once-Daily LY3502970 Compared With Placebo in Participants Who Have Obesity or Are Overweight With Weight-Related Comorbidities2021 · 272 randomized · 36 weeks